10 20 30 40 50 60 70 80 2V22 - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER TRANSFERASE 31-MAY-07 2V22
TITLE REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING TITLE 2 GROOVE INHIBITORS
COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: P33 PROTEIN KINASE, CYCLIN-DEPENDENT KINASE 2; COMPND 5 EC: 2.7.1.37; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: TRIAZOL-1-METHYL-PYRIMIDIN INHIBITOR; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: CYCLIN-A2; COMPND 10 CHAIN: B, D; COMPND 11 SYNONYM: CYCLIN-A; COMPND 12 ENGINEERED: YES; COMPND 13 OTHER_DETAILS: CAP-TETRAPEPTIDE INHIBITOR
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 7 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 562
KEYWDS POLYMORPHISM, CYCLIN GROOVE, CELL DIVISION, CDK2, KINASE, KEYWDS 2 CYCLIN, ACTIVE, MITOSIS, INHIBITION, PHOSPHORYLATION, KEYWDS 3 NUCLEOTIDE-BINDING, SERINE/THREONINE-PROTEIN KINASE, CELL KEYWDS 4 CYCLE, NONPEPTIDE, TRANSFERASE, ATP-BINDING
EXPDTA X-RAY DIFFRACTION
AUTHOR M.J.ANDREWS,G.KONTOPIDIS,C.MCINNES,A.PLATER,L.INNES,A.COWAN, AUTHOR 2 P.JEWSBURY,P.M.FISCHER
REVDAT 2 24-FEB-09 2V22 1 VERSN REVDAT 1 29-JAN-08 2V22 0
JRNL AUTH M.J.ANDREWS,G.KONTOPIDIS,C.MCINNES,A.PLATER, JRNL AUTH 2 L.INNES,A.COWAN,P.JEWSBURY,P.M.FISCHER JRNL TITL REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF JRNL TITL 2 CYCLIN- BINDING GROOVE INHIBITORS JRNL REF CHEMBIOCHEM V. 7 1909 2006 JRNL REFN ISSN 1439-4227 JRNL PMID 17051658 JRNL DOI 10.1002/CBIC.200600189
REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH G.KONTOPIDIS,C.MCINNES,S.R.PANDALANENI,I.MCNAE, REMARK 1 AUTH 2 D.GIBSON,M.MEZNA,M.THOMAS,G.WOOD,S.WANG, REMARK 1 AUTH 3 M.D.WALKINSHAW,P.M.FISCHE REMARK 1 TITL DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND REMARK 1 TITL 2 INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 1 REF CHEM.BIOL. V. 13 201 2006 REMARK 1 REFN ISSN 1074-5521 REMARK 1 PMID 16492568 REMARK 1 DOI 10.1016/J.CHEMBIOL.2005.11.011
REMARK 2 REMARK 2 RESOLUTION. 2.60 ANGSTROMS.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.60 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 16.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 94.9 REMARK 3 NUMBER OF REFLECTIONS : 38024 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.174 REMARK 3 R VALUE (WORKING SET) : 0.171 REMARK 3 FREE R VALUE : 0.277 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1231 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.60 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.67 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2677 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2490 REMARK 3 BIN FREE R VALUE SET COUNT : 92 REMARK 3 BIN FREE R VALUE : 0.3810 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 8924 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 110 REMARK 3 SOLVENT ATOMS : 323 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 53.29 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -2.65000 REMARK 3 B22 (A**2) : -1.14000 REMARK 3 B33 (A**2) : 3.80000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 1.815 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.367 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.262 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 12.366 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.957 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.889 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 9262 ; 0.010 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 12580 ; 1.694 ; 1.987 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 1104 ; 8.734 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 394 ;41.948 ;23.959 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 1616 ;20.279 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 44 ;21.205 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 1422 ; 0.140 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 6914 ; 0.011 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 4472 ; 0.266 ; 0.300 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 6354 ; 0.334 ; 0.500 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 692 ; 0.224 ; 0.500 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 37 ; 0.372 ; 0.300 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 10 ; 0.269 ; 0.500 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 5657 ; 3.611 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 9034 ; 5.528 ; 2.000 REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 3983 ; 8.970 ; 3.000 REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 3546 ;11.930 ; 4.500 REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : 2 REMARK 3 REMARK 3 NCS GROUP NUMBER : 1 REMARK 3 CHAIN NAMES : A C REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 1 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 A 1 A 296 3 REMARK 3 1 C 1 C 296 3 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 TIGHT POSITIONAL 1 A (A): 1184 ; 0.24 ; 0.05 REMARK 3 LOOSE POSITIONAL 1 A (A): 1194 ; 0.61 ; 5.00 REMARK 3 TIGHT THERMAL 1 A (A**2): 1184 ; 1.39 ; 0.50 REMARK 3 LOOSE THERMAL 1 A (A**2): 1194 ; 5.37 ; 10.00 REMARK 3 REMARK 3 NCS GROUP NUMBER : 2 REMARK 3 CHAIN NAMES : B D REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 1 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 B 175 B 432 4 REMARK 3 1 D 175 D 432 4 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 MEDIUM POSITIONAL 2 B (A): 2083 ; 0.40 ; 0.50 REMARK 3 MEDIUM THERMAL 2 B (A**2): 2083 ; 3.57 ; 2.00 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE REMARK 3 RIDING POSITIONS. CHAIN A AND C RESIDUES 12-17, 37-41, 159-162
REMARK 4 REMARK 4 2V22 COMPLIES WITH FORMAT V. 3.15, 01-DEC-08
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 31-MAY-07. REMARK 100 THE PDBE ID CODE IS EBI-32669.
REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 14-FEB-03 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.933 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 126787 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.60 REMARK 200 RESOLUTION RANGE LOW (A) : 20.00 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.0 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.4 REMARK 200 DATA REDUNDANCY : 3.4 REMARK 200 R MERGE (I) : 0.11 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 13.20 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.60 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.74 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.0 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 1.06 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 1OL1 REMARK 200 REMARK 200 REMARK: NONE
REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.7 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 22% PEG 3350, 0.1M NA3-CIT
REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 37.34650 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 78.01250 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 56.78550 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 78.01250 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 37.34650 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 56.78550 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL
REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA.
REMARK 350 REMARK 350 GENERATING THE BIOMOLECULE REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TETRAMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 TOTAL BURIED SURFACE AREA: 9370 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 55940 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -20.2 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ARG A 297 REMARK 465 LEU A 298 REMARK 465 GLU B 174 REMARK 465 LEU C 298 REMARK 465 GLU D 174
REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LEU B 432 O REMARK 470 ARG C 297 CA C O CB CG CD NE CZ NH1 NH2
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O ASP C 38 - N GLU C 40 2.10 REMARK 500 O TYR C 159 - N HIS C 161 1.97 REMARK 500 NZ LYS C 278 - O ASP D 177 2.11 REMARK 500 O HOH A 2048 - O HOH A 2050 2.16 REMARK 500 O HOH C 2015 - O HOH C 2038 2.07 REMARK 500 O HOH C 2024 - O HOH C 2027 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 LYS C 242 CD LYS C 242 CE 0.165 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 PRO C 234 C - N - CA ANGL. DEV. = 9.0 DEGREES REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 14 110.24 35.82 REMARK 500 ASP A 38 91.22 -59.93 REMARK 500 GLU A 40 9.09 -152.83 REMARK 500 THR A 41 -35.10 -149.97 REMARK 500 ASP A 68 149.43 -173.48 REMARK 500 LEU A 96 -25.75 82.44 REMARK 500 LEU A 101 -54.80 -28.81 REMARK 500 ARG A 126 -15.21 83.89 REMARK 500 ASP A 145 75.27 60.50 REMARK 500 VAL A 164 33.68 -152.82 REMARK 500 THR A 165 145.92 63.56 REMARK 500 ARG A 199 -0.89 84.05 REMARK 500 SER A 232 41.30 -106.03 REMARK 500 PRO A 234 -37.07 -37.83 REMARK 500 PRO A 238 -8.26 -59.96 REMARK 500 ARG A 245 93.48 -62.82 REMARK 500 PRO A 254 4.19 -64.93 REMARK 500 PRO A 284 -27.67 -37.92 REMARK 500 THR A 290 -169.07 -123.61 REMARK 500 ASP B 284 36.65 34.83 REMARK 500 THR B 303 42.17 38.94 REMARK 500 TRP B 372 102.87 -36.51 REMARK 500 SER B 375 -53.34 -26.71 REMARK 500 LEU B 424 158.22 -39.91 REMARK 500 THR C 14 72.00 56.16 REMARK 500 LEU C 37 69.17 -110.67 REMARK 500 ASP C 38 81.36 -49.17 REMARK 500 THR C 39 48.56 -41.68 REMARK 500 GLU C 40 -41.83 -146.68 REMARK 500 THR C 41 -105.40 -68.24 REMARK 500 LEU C 96 -20.01 80.08 REMARK 500 ARG C 126 -15.43 68.73 REMARK 500 ASP C 145 76.41 52.95 REMARK 500 TYR C 159 98.38 -53.36 REMARK 500 THR C 160 62.04 -41.65 REMARK 500 HIS C 161 106.10 70.16 REMARK 500 ARG C 199 11.45 85.74 REMARK 500 PRO C 254 1.31 -58.57 REMARK 500 PRO D 176 169.76 -41.88 REMARK 500 ASP D 283 43.36 78.81 REMARK 500 THR D 303 47.89 38.12 REMARK 500 PHE D 304 11.31 52.45 REMARK 500 ASN D 326 118.89 -169.14 REMARK 500 TRP D 372 114.20 -38.70 REMARK 500 LEU D 384 -35.89 -39.12 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ILE A 70 HIS A 71 -148.11 REMARK 500 ILE C 70 HIS C 71 -136.69 REMARK 500 HIS C 161 GLU C 162 -138.77 REMARK 500 GLY D 198 TYR D 199 -134.42 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CHIRAL CENTERS REMARK 500 REMARK 500 UNEXPECTED CONFIGURATION OF THE FOLLOWING CHIRAL REMARK 500 CENTER(S) USING IMPROPER CA--C--CB--N CHIRALITY REMARK 500 M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,6X,F5.1,6X,A1,10X,A1,3X,A16) REMARK 500 REMARK 500 M RES CSSEQI IMPROPER EXPECTED FOUND DETAILS REMARK 500 TYR B 347 18.8 L L OUTSIDE RANGE REMARK 500 THR C 39 24.6 L L OUTSIDE RANGE REMARK 500 ASN C 74 24.0 L L OUTSIDE RANGE REMARK 500 ASP D 177 22.9 L L OUTSIDE RANGE REMARK 500 LYS D 252 23.7 L L OUTSIDE RANGE REMARK 500 REMARK 500 REMARK: NULL
REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE):
REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE C35 B1433 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE C35 D1433
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED REMARK 900 ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE REMARK 900 COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN REMARK 900 CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 REMARK 900 (CDK2) IN COMPLEX WITH 4-[3- REMARK 900 HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN REMARK 900 A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5- REMARK 900 SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS REMARK 900 CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT REMARK 900 KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED REMARK 900 PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 REMARK 900 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX REMARK 900 WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT REMARK 900 KINASE 2 (CDK2)IN COMPLEX WITH THE REMARK 900 INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, REMARK 900 NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL- REMARK 900 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN REMARK 900 COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R REMARK 900 )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN REMARK 900 COMPLEX WITH THE INHIBITOR 2-AMINO-6-[ REMARK 900 CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE REMARK 900 RECRUITMENT PEPTIDE FROM E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE REMARK 900 RECRUITMENT PEPTIDE FROM E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE REMARK 900 RECRUITMENT PEPTIDE FROM P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE REMARK 900 RECRUITMENT PEPTIDE FROM P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE REMARK 900 RECRUITMENT PEPTIDE FROM P107 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND REMARK 900 TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 REMARK 900 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4- REMARK 900 PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( REMARK 900 UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- REMARK 900 1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL] REMARK 900 AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED REMARK 900 WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO REMARK 900 -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- REMARK 900 YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED REMARK 900 WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2- REMARK 900 BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- REMARK 900 OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2- REMARK 900 ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED REMARK 900 WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3 REMARK 900 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- REMARK 900 YL)BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED REMARK 900 WITH 3-{[4-({[AMINO(IMINO)METHYL] REMARK 900 AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4- REMARK 900 CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS REMARK 900 OF CYCLIN-DEPENDENT KINASE INHIBITORS REMARK 900 IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS REMARK 900 OF CYCLIN-DEPENDENT KINASE INHIBITORS REMARK 900 IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS REMARK 900 OF CYCLIN-DEPENDENT KINASE INHIBITORS REMARK 900 IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- REMARK 900 ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- REMARK 900 ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- REMARK 900 CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- REMARK 900 ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 REMARK 900 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN REMARK 900 COMPLEX WITH THEINHIBITOR 4,5,6,7- REMARK 900 TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT REMARK 900 KINASE 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX REMARK 900 WITH PHOSPHO-CDK2/CYCLIN A REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT REMARK 900 KINASE 2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN- REMARK 900 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL- REMARK 900 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- REMARK 900 THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- REMARK 900 HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL- REMARK 900 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- REMARK 900 PHENYL)-AMINE REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR 3-[4-(2,4-DIMETHYL- REMARK 900 THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR 4-[4-(4-METHYL-2- REMARK 900 METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- REMARK 900 YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR [4-(2-AMINO-4-METHYL- REMARK 900 THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- REMARK 900 PHENYL)-AMINE REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- REMARK 900 THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- REMARK 900 DIMETHYL-BENZENE-1,4-DIAMINE REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE REMARK 900 PEPTIDE COMPLEX REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- REMARK 900 ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] REMARK 900 PYRIDAZINE REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX REMARK 900 WITH THE INHIBITOR OLOMOUCINE. REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- REMARK 900 8-ISOPROPYL-9H-PURIN-2-YLAMINE AND REMARK 900 MONOMERIC CDK2 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY REMARK 900 CYCLIN E REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY REMARK 900 CRYSTALLOGRAPHY REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1YKR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH AN REMARK 900 AMINOIMIDAZO PYRIDINEINHIBITOR REMARK 900 RELATED ID: 2A0C RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, REMARK 900 A NOVEL 2,6,9-TRISUBSTITUTED PURINE CYCLIN REMARK 900 -DEPENDENT KINASE INHIBITOR REMARK 900 RELATED ID: 2A4L RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX REMARK 900 WITH ROSCOVITINE REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) REMARK 900 COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) REMARK 900 COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) REMARK 900 COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) REMARK 900 COMPLEXED WITHINDENOPYRAXOLE DIN-101312 REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN REMARK 900 COMPLEX WITH THE INHIBITOR 5-BROMO- REMARK 900 INDIRUBINE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN REMARK 900 COMPLEX WITH THE INHIBITOR 4- REMARK 900 HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2C5T RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN REMARK 900 COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED REMARK 900 FROM CDC MODIFIED WITH A GAMMA-LINKED ATP REMARK 900 ANALOGUE REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A REMARK 900 IN COMPLEX WITH A PEPTIDE CONTAINING BOTH REMARK 900 THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE REMARK 900 PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX REMARK 900 WITH CYCLIN A STRUCTURE REMARK 900 RELATED ID: 2CLX RELATED DB: PDB REMARK 900 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK REMARK 900 INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN REMARK 900 COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR REMARK 900 EFFECTS REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- REMARK 900 CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- REMARK 900 CYCLIN A F82H-L83V-H84D MUTANT WITH AN REMARK 900 O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR REMARK 900 RELATED ID: 2IW9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- REMARK 900 CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2J9M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH REMARK 900 MACROCYCLIC AMINOPYRIMIDINE REMARK 900 RELATED ID: 2JGZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX REMARK 900 WITH CYCLIN B REMARK 900 RELATED ID: 2UUE RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF REMARK 900 CYCLIN BINDING GROOVE INHIBITORS REMARK 900 RELATED ID: 2UZB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2UZD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2UZE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2UZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2UZN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2UZO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2V0D RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR
DBREF 2V22 A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2V22 C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2V22 B 174 432 UNP P20248 CCNA2_HUMAN 174 432 DBREF 2V22 D 174 432 UNP P20248 CCNA2_HUMAN 174 432
SEQRES 1 A 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 A 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 A 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 A 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 A 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 A 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 A 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 A 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 A 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 A 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 A 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 A 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 A 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 A 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 A 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 A 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 A 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 A 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 A 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 A 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 A 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 A 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 A 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 B 259 GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU SEQRES 2 B 259 ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR SEQRES 3 B 259 MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA SEQRES 4 B 259 ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR SEQRES 5 B 259 LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR SEQRES 6 B 259 ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY SEQRES 7 B 259 LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SEQRES 8 B 259 SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU SEQRES 9 B 259 PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN SEQRES 10 B 259 VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR SEQRES 11 B 259 PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR SEQRES 12 B 259 GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL SEQRES 13 B 259 GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE SEQRES 14 B 259 ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE SEQRES 15 B 259 ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR SEQRES 16 B 259 GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY SEQRES 17 B 259 TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU SEQRES 18 B 259 HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SEQRES 19 B 259 SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY SEQRES 20 B 259 VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 C 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 C 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 C 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 C 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 C 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 C 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 C 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 C 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 C 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 C 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 C 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 C 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 C 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 C 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 C 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 C 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 C 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 C 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 C 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 C 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 C 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 C 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 C 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 D 259 GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU SEQRES 2 D 259 ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR SEQRES 3 D 259 MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA SEQRES 4 D 259 ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR SEQRES 5 D 259 LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR SEQRES 6 D 259 ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY SEQRES 7 D 259 LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SEQRES 8 D 259 SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU SEQRES 9 D 259 PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN SEQRES 10 D 259 VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR SEQRES 11 D 259 PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR SEQRES 12 D 259 GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL SEQRES 13 D 259 GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE SEQRES 14 D 259 ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE SEQRES 15 D 259 ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR SEQRES 16 D 259 GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY SEQRES 17 D 259 TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU SEQRES 18 D 259 HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SEQRES 19 D 259 SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY SEQRES 20 D 259 VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU
HET C35 B1433 55 HET C35 D1433 55
HETNAM C35 N~2~-{[1-(4-CHLOROPHENYL)-5-METHYL-1H-1,2,4- HETNAM 2 C35 TRIAZOL-3-YL]CARBONYL}-N~5~- HETNAM 3 C35 (DIAMINOMETHYLIDENE)-L-ORNITHYL-L-LEUCYL-L-ISOLEUCYL-4-FLUORO- HETNAM 4 C35 L-PHENYLALANINAMIDE
FORMUL 5 C35 2(C37 H51 CL F N11 O5) FORMUL 6 HOH *323(H2 O1)
HELIX 1 1 PRO A 45 LEU A 58 1 14 HELIX 2 2 LEU A 87 SER A 94 1 8 HELIX 3 3 PRO A 100 SER A 120 1 21 HELIX 4 4 LYS A 129 GLN A 131 5 3 HELIX 5 5 ALA A 170 LEU A 175 1 6 HELIX 6 6 THR A 182 ARG A 199 1 18 HELIX 7 7 SER A 207 GLY A 220 1 14 HELIX 8 8 GLY A 229 MET A 233 5 5 HELIX 9 9 ASP A 247 VAL A 252 1 6 HELIX 10 10 ASP A 256 LEU A 267 1 12 HELIX 11 11 ASP A 270 ARG A 274 5 5 HELIX 12 12 SER A 276 ALA A 282 1 7 HELIX 13 13 HIS A 283 GLN A 287 5 5 HELIX 14 14 TYR B 178 CYS B 193 1 16 HELIX 15 15 THR B 207 TYR B 225 1 19 HELIX 16 16 GLN B 228 MET B 246 1 19 HELIX 17 17 LYS B 252 GLU B 269 1 18 HELIX 18 18 GLU B 274 THR B 282 1 9 HELIX 19 19 THR B 287 LEU B 302 1 16 HELIX 20 20 THR B 310 LEU B 320 1 11 HELIX 21 21 ASN B 326 ASP B 343 1 18 HELIX 22 22 ASP B 343 LEU B 348 1 6 HELIX 23 23 LEU B 351 GLY B 369 1 19 HELIX 24 24 PRO B 373 GLY B 381 1 9 HELIX 25 25 THR B 383 SER B 386 5 4 HELIX 26 26 LEU B 387 ALA B 401 1 15 HELIX 27 27 PRO B 402 HIS B 404 5 3 HELIX 28 28 GLN B 407 TYR B 413 1 7 HELIX 29 29 LYS B 414 HIS B 419 5 6 HELIX 30 30 PRO C 45 LEU C 58 1 14 HELIX 31 31 LEU C 87 ALA C 93 1 7 HELIX 32 32 PRO C 100 HIS C 121 1 22 HELIX 33 33 LYS C 129 GLN C 131 5 3 HELIX 34 34 ASP C 145 ALA C 149 5 5 HELIX 35 35 ALA C 170 LEU C 175 1 6 HELIX 36 36 THR C 182 ARG C 199 1 18 HELIX 37 37 SER C 207 GLY C 220 1 14 HELIX 38 38 GLY C 229 MET C 233 5 5 HELIX 39 39 ASP C 247 VAL C 252 1 6 HELIX 40 40 ASP C 256 LEU C 267 1 12 HELIX 41 41 SER C 276 LEU C 281 1 6 HELIX 42 42 ALA C 282 VAL C 289 5 8 HELIX 43 43 TYR D 178 CYS D 193 1 16 HELIX 44 44 GLY D 198 GLN D 203 5 6 HELIX 45 45 THR D 207 TYR D 225 1 19 HELIX 46 46 GLN D 228 MET D 246 1 19 HELIX 47 47 LEU D 249 GLY D 251 5 3 HELIX 48 48 LYS D 252 GLU D 269 1 18 HELIX 49 49 GLU D 274 ILE D 281 1 8 HELIX 50 50 THR D 287 LEU D 302 1 16 HELIX 51 51 THR D 310 PHE D 319 1 10 HELIX 52 52 LEU D 320 GLN D 322 5 3 HELIX 53 53 ASN D 326 ASP D 343 1 18 HELIX 54 54 ASP D 343 LEU D 348 1 6 HELIX 55 55 LEU D 351 THR D 368 1 18 HELIX 56 56 PRO D 373 GLY D 381 1 9 HELIX 57 57 LEU D 387 ALA D 401 1 15 HELIX 58 58 GLN D 407 TYR D 413 1 7 HELIX 59 59 LYS D 414 HIS D 419 5 6
SHEET 1 AA 5 PHE A 4 GLU A 12 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLU C 12 0 SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 ILE C 70 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124
CISPEP 1 GLN B 323 PRO B 324 0 5.92 CISPEP 2 GLN D 323 PRO D 324 0 -12.71 CISPEP 3 ASP D 345 PRO D 346 0 7.99
SITE 1 AC1 18 GLU A 12 THR A 14 ASP A 127 LYS A 129 SITE 2 AC1 18 LEU A 148 VAL A 163 VAL A 164 MET B 210 SITE 3 AC1 18 LEU B 214 TRP B 217 GLU B 224 ARG B 250 SITE 4 AC1 18 LEU B 253 GLN B 254 ILE B 281 THR B 282 SITE 5 AC1 18 ASP B 283 HOH B2082 SITE 1 AC2 12 ASP C 247 MET D 210 LEU D 214 TRP D 217 SITE 2 AC2 12 ARG D 250 GLN D 254 ILE D 281 THR D 282 SITE 3 AC2 12 ASP D 283 THR D 285 HOH D2091 HOH D2094
CRYST1 74.693 113.571 156.025 90.00 90.00 90.00 P 21 21 21 8
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.013388 0.000000 0.000000 0.00000
SCALE2 0.000000 0.008805 0.000000 0.00000
SCALE3 0.000000 0.000000 0.006409 0.00000